For more than 50 years we at Sysmex have paired our high-quality haematology analysers with the knowledge of our customers and medical experts, resulting in solutions for profound blood cell characterisation: from cell count to cell morphology and functionality, to clinical flow cytometry and its dedicated antibodies.

We have moved beyond the traditional complete blood count (CBC) and arrived at aid to diagnosis solutions allowing an unmatched level of insight in patients haematopoiesis and blood cell physiology – supporting better and faster detection and treatment of haematologic malignancies.

You are welcome to explore how our clinical insights can support you in diagnostics and therapy decision making.

Smartly linked APL diagnostics

A clinical challenge: acute promyelocytic leukaemia (APL) is a medical emergency, but it is rare, and symptoms are non-specific.

APL is a distinct form of acute myeloid leukaemia strongly associated with dysregulated coagulation, very frequently resulting in disseminated intravascular coagulopathy (DIC), which can cause life-threatening bleeding and thrombotic complications, especially in the early stages of the disease.

APL is highly curable if recognised early and promptly treated.
Delay results in the rapid evolution of bleeding abnormalities with a high mortality rate.
Improved linkage of diagnostic information from haemostasis, haematology, and clinical flow cytometry allows for earlier recognition of suspected APL, followed by genetic confirmation, which is essential for the timely design of a targeted treatment plan.

Learn more about acute promyelocytic leukaemia

Incidential finding of suspected malignant cells

Recognize the early signs of leukaemia already from standard blood cell count analysis

Are you aware that routine blood count can aid in the incidental findings of haematologic malignancies? The studies showed that with the analysis of blood sample on XR-Series or XN-Series haematology analyser you can increase your confidence about

Sensitive detection of pathologic cells
Suspicious samples immediately directed for follow-up review
Not missing suspected malignant samples early on [1-4]

Learn more about Sysmex's solutions

Stem cell transplantation

Observe early signs of successful stem cell engraftment

Just by blood cell counting: Closely monitor your patients and get supportive answers for:

Have the transplanted stem cells already started to produce new blood cells?
Bone marrow toxicity due to chemotherapy:
- Have the blood counts reached a critical low level due to chemotherapy?
- Are there signs of bone marrow recovery, so that transfusion could be avoided?

Explore how Sysmex haematology analysers can assist you

Anaemia in patients with haematologic malignancies

Be more confident in anaemia diagnosis and therapy

Did you know that routine blood count can aid in assessing the availability of iron in patients with haematologic malignancies?

The state-of-the-art Sysmex haematology analysers offer:

Parameter that directly reflect the bioavailability of iron for erythropoiesis [5-6]
Early indication of the response to iron therapy and/or erythropoiesis-stimulating agents [7-8]

Learn more about anaemia management in patients with haematologic malignancies

You might also be interested in ...

Good to know

Sysmex’s new flagship product line for laboratory haematology.

You can explore the XR-Series

Haematology

Knowledge Centre

Learn more

Sysmex Parameters

Advanced clinical and research parameters

Explore our parameter gallery

White papers

Haematology

Explore more

References

[1] Da Rin G et al. (2017): Performance evaluation of the automated nucleated red blood cell count of five commercial hematological analyzers. Int J Lab Hematol. Dec; 39(6): 663–70.

[2] Bruegel M et al. (2015): Comparison of five automated hematology analyzers in a university hospital setting: Abbott Cell-Dyn Sapphire, Beckman Coulter DxH 800, Siemens Advia 2120i, Sysmex XE-5000, and Sysmex XN-2000. Clin Chem Lab Med. Jun; 53(7): 1057–71.

[3] ] Blomme S et al. (2021): The integration of Sysmex XN-9100’ WPC channel reflex testing in the detection of reactive versus malignant blood samples. Int J Lab Hematol. Apr; 43(2): 191–198.

[4] Schuff-Werner P et al. (2016): Performance of the XN-2000 WPC channel-flagging to differentiate reactive and neoplastic leukocytosis. Clin Chem Lab Med. Sep 1; 54(9): 1503–10.

[5] Hoenemann C et al. (2021): Reticulocyte and Erythrocyte Hemoglobin Parameters for Iron Deficiency and Anemia Diagnostics in Patient Blood Management. A Narrative Review. J Clin Med. Sep; 10(18): 4250.

[6] Muñoz M et al. (2017): International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia. Feb; 72(2): 233–247.

[7] Almashjary MN et al. (2022): Reticulocyte Hemoglobin-Equivalent Potentially Detects, Diagnoses and Discriminates between Stages of Iron Deficiency with High Sensitivity and Specificity. J Clin Med. Sep 26; 11(19): 5675.

[8] Auerbach M et al. (2021): Using Reticulocyte Hemoglobin Equivalent as a Marker for Iron Deficiency and Responsiveness to Iron Therapy. Mayo Clin Proc. Jun; 96(6): 1510–1519.